ARTICLE | Strategy
Zai's second act
Why China in-licensing play Zai built a discovery research center
November 2, 2015 8:00 AM UTC
When Zai Laboratory Ltd. first launched in 2013, its immediate plan was to in-license programs from companies and academics in the West and Asia. Now with five licensed programs under its belt, the biotech is expanding into de novo discovery to ensure a sustainable pipeline of innovative drugs suitable for the global markets.
On Oct. 20 at BioCentury's China Healthcare Summit in Shanghai, Zai announced the opening of a new R&D center, a discovery and development collaboration with Tsinghua University Immunology Institute, and the appointment of James Yan to the newly created position of EVP and head of early development and drug safety. ...